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Initial clinical results of the bioartificial kidney containing hu-
man cells in ICU patients with acute renal failure.
Background. Acute renal failure (ARF) in intensive care
unit patients continues to have mortality rates exceeding 70%,
despite hemodialysis or continuous renal replacement therapy
(CRRT). The delivery of cellular metabolic function to CRRT
may provide more complete renal replacement therapy, thereby
changing the natural history of this disease process. An FDA-
approved Phase I/II clinical trial on 10 patients has been com-
pleted, and demonstrated that this experimental treatment can
be delivered safely for up to 24 hours.
Methods. The bioartificial kidney is a synthetic hemofilter
connected in series with a bioreactor cartridge containing ap-
proximately 109 human proximal tubule cells, as a renal tubule
assist device (RAD), within an extracorporeal perfusion circuit
utilizing standard hemofiltration pump systems. All 10 patients
had ARF and multiorgan failure (MOF), with predicted hospi-
tal mortality rates averaging above 85%.
Results. Data indicate that the RAD maintains viability, dura-
bility, and functionality in this ex vivo clinical setting. The device
also demonstrated differentiated metabolic and endocrinologic
activity, with glutathione degradation and endocrinologic con-
version of 25-OH-D3 to 1,25-(OH)2-D3. All but one treated pa-
tient with more than a 3-day follow-up in the intensive care unit
showed improvement as assessed by acute physiologic scores 1
to 7 days following therapy. Six of the 10 treated patients sur-
vived past 30 days. One patient expired within 12 hours after
RAD treatment due to his family’s request to withdraw venti-
latory life support. Three other patients died due to complica-
tions from acute or chronic comorbidities unrelated to ARF or
RAD therapy. Plasma cytokine levels suggest that RAD ther-
apy produced dynamic and individualized responses in patients.
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For the subset of patients who had excessive proinflammatory
levels, RAD treatment resulted in significant declines in gran-
ulocyte colony stimulating factor (G-CSF), interleukin (IL)-6,
IL-10, and IL-6/IL-10 ratios.
Conclusion. The addition of human renal tubule cell therapy
to CRRT has been accomplished and demonstrates metabolic
activity with systemic effects in patients with ARF and MOF.
These initial clinical results are encouraging, so that a random-
ized, controlled Phase II clinical trial is underway to further
assess the clinical safety and efficacy of this new therapeutic
approach.
Cell therapy is one of the most exciting fields in trans-
lational medicine. It stands at the intersection of a vari-
ety of rapidly developing scientific disciplines: stem cell
biology, immunology, tissue engineering, molecular biol-
ogy, biomaterials, transplantation biology, regenerative
medicine, and clinical research. Cell-based therapy may
develop into a new therapeutic platform to treat a vast
array of clinical disorders [1]. The potential success of
this therapeutic approach lies in the growing apprecia-
tion that most disease processes are not due to the lack or
excess of a single protein, but develop due to alterations
in the complex interactions of a variety of cell products.
In addition, cells may provide a dynamic, interactive, and
individualized therapy that responds to the pathophysi-
ologic condition of the patient. This form of treatment is
dependent on cell and tissue culture methodologies to ex-
pand and supply stem/progenitor cells to replace impor-
tant differentiated processes damaged or lost in various
disease states. Recent approaches have made progress by
placing cells into hollow-fiber bioreactors or encapsulat-
ing membranes as a means to deliver cell activities to a
patient [2, 3]. A reasonable extension of this approach
is to add cell therapy to the current continuous renal re-
placement therapy (CRRT) [4].
The approach to patients with acute or chronic renal
failure using dialysis or hemofiltration is still suboptimal
in terms of morbidity and mortality [5, 6]. Poor outcomes
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may be due to the fact that these therapies substitute
for the small solute clearance function of the kidney but
do not replace the lost reclamation, metabolic, and en-
docrine functions of this organ [7]. The disorder of acute
renal failure (ARF), or acute tubular necrosis (ATN),
may be especially amenable to cell therapy in conjunc-
tion with continuous hemofiltration techniques because
acute hemodialysis or hemofiltration has yet to reduce
the mortality rate of ATN below 50%, despite advances
in synthetic materials and extracorporeal circuits.
ATN develops predominantly due to the injury and
necrosis of renal proximal tubule cells. The development
of ARF in a hospitalized patient results in a 5- to 8-fold
higher risk of death [8, 9]. Improved treatment regimens
in patients with ARF in the intensive care unit (ICU)
have not shared the same quantum leaps of progress
that have been seen in other illnesses, such as myocar-
dial infarction, despite improved understanding of the
pathophysiology of the syndrome, improvements in me-
chanical ventilation, detection and treatment of infection,
and techniques for renal substitution [10]. In this regard,
the cause of death in these patients is usually the de-
velopment of systemic inflammatory response syndrome
(SIRS), often secondary to bacterial infection or sepsis,
with resulting cardiovascular collapse, ischemic damage
to vital organs, and multiorgan failure [11]. The propen-
sity of patients with ARF to develop SIRS and sepsis [12]
suggests that renal function, specifically renal tubule cell
function, plays a critical immunomodulatory role in in-
dividuals under stress states. The renal tubule cell’s roles
in glutathione reclamation, glutathione peroxidase syn-
thesis, and activation of vitamin D3, a hormone with
important immunologic functions, are well-recognized
pathways to maintaining tissue integrity and host defense
under stress conditions [7]. A less recognized role of the
renal tubule cell is its potential immunoregulatory func-
tion. Mammalian renal proximal tubule cells are immuno-
logically active. They are antigen-presenting cells [13–15]
that possess costimulatory molecules [16] and that syn-
thesize and process a variety of inflammatory cytokines
[17–21].
An extracorporeal device utilizing a standard hemofil-
tration cartridge containing approximately 109 renal
tubule cells grown as confluent monolayers along the
inner surface of the fibers has been successfully fabri-
cated [4, 22]. The nonbiodegradability and pore size of
the hollow fibers allow the membranes to act as both
scaffolds for the cells and as an immunoprotective bar-
rier. In vitro studies of this renal tubule assist device
(RAD) have demonstrated that the cells retain differenti-
ated active transport properties, differentiated metabolic
activities, and important endocrine processes [22]. Ad-
ditional studies have shown that the RAD, when incor-
porated in series with a hemofiltration cartridge in an
extracorporeal blood perfusion circuit, replaces filtration,
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Fig. 1. Schematic of the extracorporeal circuit for the perfusion of the
bioartificial kidney.
transport, metabolic, and endocrine functions of the kid-
ney in acutely uremic dogs [4]. Furthermore, recent
studies have demonstrated that the RAD ameliorates
endotoxin shock in acutely uremic animals [23, 24]. RADs
consisting of either porcine or human cells have been suc-
cessfully fabricated and tested [4, 25].
This paper summarizes the results of an FDA-approved
Phase I/II clinical study completed on 10 ICU patients
with ATN who were treated with the RAD.
METHODS
The bioartificial kidney is comprised of a continuous
venovenous hemofiltration (CVVH) circuit connected to
a synthetic hemofiltration cartridge and a RAD [4, 25].
The RAD is a commercial hemofiltration cartridge (Fre-
senius F40; Fresenius AG, Bad Homburg, Germany) in
which human renal tubule cells have been grown to con-
fluence along the inner surface of the hollow fibers [25].
The human cells were isolated and expanded from human
kidneys obtained from the National Disease Research
Interchange (NDRI, Arlington, VA, USA). NDRI is a
nonprofit organization providing tissues and organs orig-
inally retrieved for transplantation, but due to anatomic
or fibrotic defects were not suitable for transplantation.
The RAD perfusion pump system is connected in series
to a CVVH extracorporeal pump system [4, 24]. The post-
filtered blood from the CVVH circuit is pumped with a
peristaltic pump system at a rate of 150 mL/min to the
extracorporeal space of the RAD (see Fig. 1).
The ultrafiltrate (UF) formed from the synthetic
hemofilter is delivered into the fibers of the tubule lu-
mens within the RAD downstream to the hemofilter at a
rate of 10 mL/min. The hydraulic pressures within the
RAD are adjusted to reabsorb and return UF to the
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patient at a rate of 5 mL/min. Processed UF exiting the
luminal space of the RAD is collected and discarded as
“urine.” The filtered blood exiting the hemofilter enters
the RAD through the extracapillary space (ECS) port
and disperses among the fibers of the device. Upon ex-
iting the RAD, the processed blood travels through an
additional pump and is delivered back to the patient.
This additional pump is required to maintain appropriate
hydraulic pressures within the RAD. In this regard, the
pressures of the blood and UF just before entry into the
RAD are monitored. Heparin is delivered continuously
into the blood before entering the RAD to diminish clot-
ting within the device. The RAD is oriented horizontally
and placed into a temperature-controlled environment.
The temperature of the cell compartment of the RAD
is maintained at approximately 37◦C throughout its op-
eration to ensure optimal functionality of the cells. This
extracorporeal pump circuit is described in detail in prior
publications [4, 24].
This Phase I/II study was carried out at two institutions,
the University of Michigan (UM) and Cleveland Clinic
Foundation (CCF), under two sponsor-investigator In-
vestigational New Drug (IND) applications approved by
the FDA and the local Institutional Review Boards of
the UM and CCF. This report analyzes the data of 10
enrolled patients (five from each institution), and treats
the clinical study of both INDs as a single study from
the two sites. The UM and CCF RAD clinical protocols
were essentially identical, except that the UM Institu-
tional Review Board required additional inclusion cri-
teria for an existing Swan-Ganz catheter, and UM and
CCF had differing statements of exclusion of patients
with severe chronic liver disease. The CVVH protocol
followed in most elements the local institutional prac-
tices regarding replacement fluid composition and anti-
coagulant dosing. Key elements in the CRRT modalities
at the two institutions were the following: the UM study
used a GambroAK1O and CCF used a Baxter BM11 for
the hemofiltration pump system. Both institutions primed
the RAD extracorporeal system with heparinized saline
containing 1000 U/L. Hemofilters (Fresenius F40) were
changed within four hours of the initiation of RAD ther-
apy. At UM, heparin was infused pre-hemofilter; at CCF,
it was administered post-hemofilter and pre-RAD.
The primary objective of the study was to evaluate the
safety of the RAD in the ARF population being treated
with CRRT. The RAD treatment was provided in addi-
tion to the standard ICU treatment that patients receive
in this clinical setting. The primary efficacy end point
was 30-day survival. Secondary objectives included as-
sessment of surrogate efficacy parameters, including renal
parameters of blood urea nitrogen (BUN), serum crea-
tinine, and urine output, along with examination of the
effects of the RAD on the cardiovascular and respiratory
systems.
All patients enrolled in the study were hospitalized in
the ICU with ARF secondary to ATN and treated with
CRRT for at least six hours prior to enrollment in the
study. The inclusion and exclusion criteria also required
that patients had an existing arterial line, had an acute
physiologic score (APS) of between 50 and 120, were non-
pregnant, were older than 18 years, had no contraindica-
tions to systemic anticoagulation with heparin, and were
free of metastatic malignancy, severe chronic liver failure,
irreversible brain damage, and aminoglycoside adminis-
tration in the 48 hours prior to study. The patients or their
guardian(s) were required to give informed consent, and
the investigator had the flexibility to exclude any patient
with a medical condition that might interfere with the
study objectives.
Every patient enrolled in the study was seriously ill,
and along with ARF had multiple concomitant illnesses,
which included different combinations of sepsis, multiple
organ failure (MOF), acute respiratory distress syndrome
(ARDS), and various postoperative states. Because
this protocol incorporated the first use of the RAD in hu-
mans, and the patients were all in critical condition, all pa-
tients were treated and carefully monitored in ICUs. The
safety monitoring rationale was driven by the known risks
of CVVH, extracorporeal circulation and blood warming,
exposure to allogeneic cultured cells, including immuno-
logic reaction and infectious disease transmission, pre-
clinical observations of hypotension and hypoglycemia
with RAD treatment [4, 24], and standard measurements
related to the enrolled patients’ individual diagnoses and
medical conditions.
Each patient was eligible to receive up to 24 hours of
continuous RAD treatment. Only one RAD was used
on each patient. To address the safety concerns defined
above, each patient on RAD therapy was closely fol-
lowed with hemodynamic, electrolyte, and blood gas as-
sessments, along with a profile of other serum chemistry
assays, including glucose and liver function assays. Glu-
cose monitoring was especially intense during the first
four hours of treatment in order to monitor and prevent
hypoglycemia (glucose <50 mg/dL) noted in animal stud-
ies and one of the five patients (patient 004) treated at the
UM. In addition, close attention was paid to any clinical
or laboratory signs of bleeding. All patients were anti-
coagulated with heparin at doses typically used at each
institution for extracorporeal circuit perfusion (average
loading dose of 1000 U and a maintenance dose of 500 to
1000 U/hr at the UM, and no loading dose and a mainte-
nance dose between 250 to 1000 U/hr at the CCF). Lastly,
fluid balance and fluid shifts were closely monitored, with
treatment administered according to individual require-
ments.
The cytokine assays on plasma samples employed a
quantitative sandwich enzyme immunoassay technique
utilizing enzyme-linked immunosorbent assay (ELISA)
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Table 1. Clinical summary of patient condition and outcome.
Predicted
hospital Organ RAD Rx
Patient Clinical condition mortalitya failure no.b time hours Clinical outcome
001 29 yrs male Toxic shock syndrome, gram (+) septic
shock, ARDS, ARF, ischemic
heptatitis, rhabdomyolysis
92% 5 21.5 Survived, discharged with normal renal,
pulmonary, and liver function
002 70 yrs female Aspiration pneumonia, Klebsiella
pneumonia, gram (+) septic shock,
ARF, acute MI
94% 4 14.5 Survived, discharged with normal renal,
pulmonary, and cardiac function
003 26 yrs female SLE on steroids, necrotizing pancreatitis,
septic shock, ARF, acute MI
81% 5 24 Initial improvement and extubation, died 10
days after RAD Rx secondary to SLE
flare, high-dose steroids, and VRE sepsis.
Fungal pericarditis on post-mortem
004 32 yrs male MVA, aspiration pneumonia, gram (+)
sepsis, ARF, ARDS
97% 4 4.5 Survived, discharged with normal renal and
pulmonary function
005 75 yrs female Occluded aortofemoral bypass graft,
occluded femoral artery; ARF
secondary to rhabdomyolysis,
pulmonary insufficiency, hepatic
dysfunction, MI
93% 5 10.5 Improved cardiac index and extubation after
RAD; died 6 days post-RAD of MI,
hypotension, ischemic colitis, bowel
perforation
025 22 yrs male Ethylene glycol poisoning-induced ARF,
multilobar aspiration pneumonia
55% 2 24 Survived, discharged, renal function
recovered
026 75 yrs male Perforated viscus, postsurgery ARDS,
septicemia, liver dysfunction, ARF
93% 6 24 Stabilized arterial blood gases, died after life
support withdrawn 12 hours
post-treatment upon relatives’ request
027 60 yrs male Abdominal aneurysm, nephrectomy,
post-surgery aspiration pneumonia,
ARDS, MOF, ARF
91% 4 24 Survived, improved oxygenation, reduced
WBC, reduced bilirubin; survived past
30-day end point; two months after RAD
treatment, GI bleeding complications and
continuing downward clinical course
prompted withdrawal of life support by
family
028 45 yrs male Acute coronary syndrome, post-coronary
artery bypass operation, ARDS and
ARF
88% 4 24 Survived, improved pulmonary function with
RAD, discharged 14 days after RAD
therapy with full renal function recovery
029 59 yrs female Central line sepsis, toxic shock-like
syndrome with MOF and ARF
78% 5 12 Emergency surgery for toxic megacolon
required RAD discontinuation after
12-hour run with patient improving;
postsurgery had continuing deterioration
of MOF with decision to withdraw life
support 9 days after RAD therapy
Abbreviations are: ARDS, acute respiratory distress syndrome; MI, myocardial infarction; MOF, multiorgan failure; MVA, motor vehicle accident; SLE, systemic
lupus erythematosis; VRE, vancomycin-resistant enterococcus.
aFor patients 001 to 005, predicted mortality at the start of RAD therapy was determined by Apache III [35]. For patients 025 to 029, predicted mortality at the start
of RAD therapy was determined by Paganini score [39].
bOrgan failure definitions: 1, kidney (all patients); 2, cardiovascular: vasopressor therapy or systolic blood pressure or mean arterial pressure ≤90 or ≤70 mm Hg,
respectively; 3, respiratory: ventilator requirement or PaO2/FiO2 <150; 4, hematologic: platelet count ≤100,000; 5, liver: bilirubin ≥2.5 mg/dL; 6, gastrointestinal: GI
bleeding, pancreatitis, or perforated viscus.
kits from R&D Systems, Inc. (Minneapolis, MN, USA).
Plasma cytokine concentrations were then calculated ac-
cording to the measurements of the known concentra-
tions of the standards. Blood samples were drawn from
the patient prior to initiation of RAD therapy (0 h), upon
termination of RAD therapy, and four hours after com-
pletion of RAD therapy. A variety of cytokines were
evaluated. During the course of the study, the data sug-
gested that several plasma cytokine levels were demon-
strating substantive changes during therapy. Accordingly,
the following cytokine levels were determined in the
stored plasma samples: granulocyte-colony stimulating
factor (G-CSF), interleukin (IL)-6, IL-10, IL-8, and tu-
mor necrosis factor (TNF)-a. Cytokine levels were not
available for patient 004 due to the short duration of this
patient’s RAD treatment.
RESULTS
A total of 10 patients who met all inclusion and exclu-
sion criteria were enrolled into this study. Five patients
were enrolled at the UM and five at the CCF. There were
no study dropouts among the enrolled patients, although
five patients terminated RAD therapy before the com-
pletion of the anticipated 24 hours of therapy for rea-
sons detailed below. A clinical summary of these 10 pa-
tients with additional important information is detailed in
Table 1.
Safety profile
The clinical trial was overseen by an independent Data
Safety Monitoring Committee (DMC) comprised of four
individuals with clinical and statistical expertise. The
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review of the data by the DMC with the principal
investigators at both sites resulted in the following
assessments.
Considering the severity of illnesses of the enrolled
patients in the RAD trial, it was expected that a number
of both adverse and serious adverse reactions (death in-
cluded) would occur during the course of this trial. The
most frequent of the 42 adverse events (AEs) reported
during RAD therapy and the subsequent 24-hour period
were hypotension or hypovolemia [6], thrombocytope-
nia [4], and hyperglycemia [6]. Hypotension during this
study was difficult to define in a consistent manner. Be-
cause the blood pressure of these critically ill patients
will be dependent upon volume status, volume resuscita-
tion, and pressor requirements, and varies hour to hour
in the ICU setting, we agreed with the FDA to make this
assessment by relying on the clinical investigators to de-
termine whether hypotension occurred during treatment.
In this regard, six hypotensive events were identified dur-
ing this study. Review of the cases demonstrated that four
of these six episodes occurred within the first 15 minutes
of RAD therapy, most likely due to a decline in intravas-
cular volume secondary to the blood volume required in
the extracapillary space of the RAD cartridge. The other
two hypotensive events occurred at eight and 13 hours
after RAD therapy was initiated, and were attributable
to underlying acute and chronic comorbidities of the
treated patient. The only significant hypotensive event
occurred in 002, in which an increase of pressor support
exceeded two times the baseline infusion rate and trig-
gered discontinuation of the RAD due to a predefined
trigger point. All of the instances of hypotension resolved
with standard care, except for ongoing hypotension ex-
perienced by patient 029, which was most likely caused
by the development of non–RAD-related toxic mega-
colon secondary to Clostridium difficile infection during
RAD treatment. The absolute values and the clinical in-
vestigators’ assignment of the level of intensity as mild,
moderate, or severe of these six episodes were: 91/54
(moderate), 97/44 (mild), 106/41 (severe), 100/41 (se-
vere), 118/55 (severe), and 96/37 (severe).
A decrease in platelet count or exacerbation of pre-
RAD thrombocytopenia was reported in four patients
and, per protocol, resulted in discontinuation of RAD
therapy in two patients who developed platelet counts
less than 35,000/mm3. Two patients received platelet
transfusions to maintain their platelet counts during
RAD therapy, although no significant clinical sequelae
(e.g., bleeding) related to thrombocytopenia were re-
ported. The development or worsening of thrombocy-
topenia in patients exposed to an extracorporeal circuit
and heparin therapy is not uncommon, although a re-
lationship to the RAD therapy cannot be excluded at
this time. Of importance, no episodes of hemofilter clot-
ting occurred in any patient during the treatment period.
Hyperglycemia (>150 mg/dL) occurred in six patients,
five of whom were administered an increased 2.5% dex-
trose concentration in the replacement fluid to prevent
the hypoglycemia experienced in patient 004 (see details
below).
Seven serious adverse events (SAEs) were reported in
the 30-day post-RAD treatment period. Six SAEs not re-
lated to RAD treatment were associated with four deaths,
along with accompanying premorbid conditions of bowel
infarction in patient 005 and toxic megacolon in patient
029. One incident of hypoglycemia was the only SAE de-
termined to be related to RAD therapy. Patient 004 expe-
rienced hypoglycemia (glucose level <40 mg/dL) shortly
after initiation of RAD therapy. The therapy was discon-
tinued. It was found that during the course of RAD fab-
rication and maintenance, insulin present in the culture
media was nonspecifically bound by the hollow fibers that
support the cells in the cartridge. This insulin was released
into the patient’s circulation during the initial phase of
RAD therapy. There was no observed detrimental ef-
fect on the patient, and the hypoglycemia was identified
quickly and the patient responded to treatment within 2
to 5 minutes. The clinical study was placed on hold un-
til a flushing procedure was developed to eliminate the
bound insulin prior to RAD administration and approved
by the FDA. No patient experienced an episode of hy-
poglycemia following the institution of this new RAD
flushing procedure.
Five patients discontinued their RAD treatment prior
to 24 hours. Two treatments were discontinued (patients
001 and 005) due to platelet counts <35,000, a clinical
protocol trigger point. RAD treatment of patient 002
was discontinued due to an increase in pressor support.
Treatment of patient 004 was discontinued due to severe
hypoglycemia. Lastly, patient 029 developed a toxic
megacolon and was taken off the RAD after 12 hours
to go to surgery for treatment of this condition.
Potential allogeneic or allergic reactions in the pa-
tients were monitored clinically. No clinical symptoma-
tology (e.g., incidences of bronchospasm) was reported
that would indicate a possible allergic reaction. Evidence
of acute infection, inflammatory reponse, hemolysis, or
hepatic injury was monitored by white blood cell (WBC)
counts and differential, free hemoglobin, lactate dehy-
drogenase (LDH), and liver function tests. Review of the
results of these tests showed no evidence of such reac-
tions. All infectious disease assays on the human proxi-
mal tubule cells (HPTC) and donor serum were negative
for HIV-1 and 2, hepatitis B and hepatitis C. All donor
serums were also negative for syphilis, and all HPTC
samples were negative for cytomegalovirus. Follow-up
serum serologic testing for these infectious agents was
performed on surviving patients at day 30 and month 6
following RAD treatment. All tests in five patients who
were available for follow-up were negative.
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Fig. 2. Plasma 1,25-(OH)2-vit D3 levels in patients with detectable lev-
els and treated with renal tubule assist device (RAD) for>20 hours.
RAD integrity and performance
After each treatment, the RADs utilized were exam-
ined. There were no cracks or leaks in the cartridge hous-
ings of any of the devices. Evaluation of hollow fiber
breakage utilizing a sensitive fluorosphere intraluminal
injection technique, consisting of microscopic assessment
of the ECS of the RAD following fluorosphere infusion,
revealed no presence of fluorosphere in the ECS. These
observations suggest no membrane breakage occurred
during the treatment period. Cell loss from the device
was assessed by cell counts in the hourly collections of
processed UF exiting the RAD during the entire treat-
ment period. The range was 3 × 105 to 1.4 × 106 cells
from an approximate total cell mass within the RAD of
approximately 0.5 to 1 × 109 cells.
Normal proximal tubule function in the kidney is char-
acterized by several transport and metabolic functional
activities that are duplicated in the RAD. These activities
were assessed in the 10 patients treated with the RAD in
the Phase I/II clinical trial. Active HCO3 transport along
the renal proximal tubule results in a decline in pH ax-
ially along the epithelial monolayer [26]. Accordingly, a
decline in pH from pre-RAD to post-RAD ultrafiltrate
(UF) was expected. All patients had a pH change near 0
or a net negative change. The mean ± SE for all patients
was −0.062 ± 0.020. Glutathione (GSH) in the kidney is
freely filtered and broken down by brush border–bound
enzymes into its constituent amino acids [27, 28]. The
amino acids are actively transported into the cell, and the
GSH is resynthesized and transported across the baso-
lateral membrane. Because of this metabolic process, the
concentration of GSH declines axially along the prox-
imal tubule. Accordingly, the ratio of GSH post-RAD
UF concentration to pre-RAD UF concentration should
be <1.0. All but one patient had an average ratio <1.0.
The overall ratio for all 10 patients averaged 0.903 ±
0.050 (SE). The proximal tubule converts 25-OH-Vit D3
to the most active vitamin D derivative, 1,25-(OH)2-Vit
D3 [29]. The loss of this proximal tubule hormonal ac-
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Fig. 3. Plasma cytokine levels in renal tubule assist device (RAD)-
treated patients. Each data point is an individual’s baseline pre-RAD
treatment level factored by the upper limit of normal for each cytokine.
Upper limit of normal levels for G-CSF = 39 pg/mL, IL-6 = 12.5 pg/mL,
IL-10 = 7.8 pg/mL, TNF-a = 15.6 pg/mL, and IL-8 = 31.2 pg/mL. The
ratios are plotted on a log scale due to the wide spectrum of values.
G-CSF, granulocyte-colony stimulating factor; IL, interleukin; TNF-a,
tumor necrosis factor-a.
tivity results in low 1,25-(OH)2-Vit D3 in renal failure.
Replacement of proximal tubule function should result
in higher 1,25-(OH)2-Vit D3 plasma levels. The analyses
of the six patients who had detectable vitamin D lev-
els post-RAD therapy and were treated for >20 hours
demonstrated RAD treatment increased 1,25-(OH)2-Vit
D3 levels from 19 ± 4.4 to 22 ± 4 pg/mL but did not reach
statistical significance. All but one patient in this subset
had increases in this parameter (Fig. 2). This patient had
severe pancreatitis and presented with a serum calcium
of 2 mg/dL. Accompanying this change was an average
increase in plasma calcium and a decrease in plasma in-
organic phosphorous in the treated patients from pre-
treatment to post-treatment values of 7.8 ± 1.0 (SD) to
8.1 ± 1.5 mg/dL and 3.4 ± 1.5 (SD) to 2.7 ± 0.8 mg/dL,
respectively.
The effect of RAD treatment on systemic plasma cy-
tokine values in patients with ARF and MOF was also
evaluated. Of importance, multiple prior studies have
demonstrated that CVVH alone at the ultrafiltration
rates used in this study does not alter plasma cytokines
in patients with SIRS [30, 31] due to the very high
rates of cytokine production. In this study, various cy-
tokines were measured prior to, at the termination of, and
four hours after RAD treatment. The data demonstrated
a wide spectrum of plasma cytokine profiles, with some
patients dramatically proinflamed, while others showing
only modest elevations of plasma levels, as detailed in
Figure 3. This observation is similar to other clinical re-
ports demonstrating variable patterns of inflammatory
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responses as SIRS evolves with time in critically ill pa-
tients [32]. This paradigm suggests that SIRS and its
attendant multiorgan dysfunction complex arises from
oscillating patterns of inflammation from systemic spread
of mediators beyond their usual autocrine or paracrine
pathways, alternating with an anti-inflammatory profile
as either compensation for, or exhaustion of, the inflam-
matory response. This futile and lethal state of affairs
has been referred to as “immunologic dissonance” [32,
33]. In acknowledgment of this immunologic spectrum,
a subset of six patients who were substantially proin-
flamed was evaluated. All patients had plasma levels
of the following cytokines assessed: TNF-a, IL-6, IL-8,
IL-10, and G-CSF. Of the cytokines tested, three ap-
peared to be substantially affected by RAD treatment:
IL-6, a prototypic initiator of inflammation; IL-10, a clas-
sic anti-inflammatory compound; and G-CSF, an impor-
tant activator and growth factor of polymorphonuclear
leukocytes [34]. As detailed in Figure 4, the effect of RAD
treatment on these plasma cytokine levels is displayed
for baseline pre-RAD treatment and post-RAD therapy
values. For the G-CSF subset, patients who had elevated
levels and were treated for >16 hours are plotted. For
the IL-6 and IL-10 subsets, patients who had levels of
both cytokines, which were greater than three-fold nor-
mal levels and were treated for >16 hours, are displayed.
All patients meeting the above criteria had lower G-CSF,
IL-6, and IL-10 levels following RAD treatment. Even
in this small group of patients these differences in cy-
tokines were statistically significant by paired t test when
the values were normalized to baseline pretreatment val-
ues: G-CSF, P = 0.0006; IL-6, P ≤ 0.5; IL-10, P = 0.02. Of
note, of the three patients that had highly elevated IL-6
and IL-10 levels, RAD treatment resulted in a significant
reduction in the IL-6 to IL-10 ratio (P = 0.025, paired t
Table 2. Acute physiologic score (APS) during intensive care unit
stay
Study timepoint APS score Minimum Maximum Sample size
Screening 88 ± 18 53 112 10
Day 1 post-therapy 81 ± 17 53 106 9
Day 2 post-therapy 78 ± 19 51 104 9
Day 3 post-therapy 69 ± 14 51 93 9
Day 4 post-therapy 67 ± 21 41 102 6
test). This decline suggests that RAD treatment was as-
sociated with a greater decline in IL-6 relative to IL-10
levels, resulting in a less proinflammatory state.
Efficacy parameters
The most likely end points of a pivotal Phase III con-
trolled clinical trial will be to assess primarily the ability
of the RAD to improve 28-day all-cause mortality, and,
secondarily, the recovery of renal function. The lack of
a control group in this Phase I/II trial allows only infer-
ences to be made as to the effect of RAD therapy on
organ failure recovery and survival. In this regard, RAD
therapy was associated with a reduction of BUN and
plasma creatinine levels from initiation to end of ther-
apy of 49.7 ± 7.8 (SE) to 40.2 ± 6.8 mg/dL and 3.42 ±
0.65 (SE) to 2.87 ± 0.5 mg/dL, respectively (P < 0.04
and P < 0.004, N = 10). This decline in renal function
parameters occurred despite a 5 mL/min rate of reab-
sorption of the delivered UF to the RAD. In two of the
younger patients, RAD treatment was temporally corre-
lated with dramatic increases in urine volume from an
oliguric/anuric state to a nonoliguric level. Of the six
treated patients who survived >30 days, only one re-
quired chronic dialysis therapy.
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Fig. 5. Acute physiologic scores (APS) for each individual patient while the patient was in the intensive care unit. Patients discharged from the
unit prior to day 7 do not have day 7 scores. Patient 026 had only a screening value since life support was discontinued 12 hours post-renal tubule
assist device (RAD) therapy.
As a reflection of multiorgan failure, each patient had
APS scores assessed at days 1, 2, 3, and 7 post-RAD treat-
ment if they remained in the ICU [35]. The APS values in
these patients are summarized in Table 2 and depicted
in individual graphs in Figure 5. Examination of APS
scores shows a trend to improvement from baseline to
days 1 through 7 post-RAD therapy, where the sample
size ranges from 10 at screening to 6 at day 7. As de-
tailed in Table 2 and Figure 5, all but one patient followed
for 3 or more days in the ICU showed improvement de-
spite multiple organ dysfunctions and an average 86%
predicted hospital mortality index. One patient (026) ex-
pired within 12 hours after RAD treatment due to his
family’s request to withdraw ventilatory life support. An-
other patient (029) expired after a surgical castastrophe
(toxic megacolon) requiring discontinuation of RAD
treatment after only 12 hours. Of the remaining eight
patients, six survived past 30 days. The two patients who
died succumbed to preexisting chronic comorbidities. Pa-
tient 003, despite an initial improvement post-RAD ther-
apy with extubation and plans to discharge from the ICU,
developed severe systemic lupus erythematosus (SLE)-
associated neutropenia. This neutropenia was treated
aggressively with high-dose steroids, and the patient sub-
sequently developed vancomycin-resistant enteroccocal
sepsis and fungal pericarditis. Due to these severe infec-
tious processes, the patient’s family elected to withdraw
life support on day 10 after RAD treatment. Patient 005
also demonstrated improvement post-RAD therapy with
extubation and plans to transfer from the ICU to an acute
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hospital bed. Unfortunately, 5 days post-treatment she
suffered a myocardial infarction with hypotension, re-
sulting in ischemic colitis and bowel perforation. The next
day her family elected to withdraw life support. Of im-
portance, without a control population and with such a
small sample size, no conclusion can be made as to the
effect of RAD treatment on survival in this study.
DISCUSSION
Acute renal failure from ATN is a common clinical dis-
order due to the high incidence of ischemic and nephro-
toxic insults to the kidney, especially in the postoperative
and ICU settings. This disease process is costly both to
health systems and to the patient. Each episode of this dis-
order prolongs a patient’s ICU or hospital stay by several
days, incurring substantial financial cost. The mortality
rate in ICU patients continues to be 50% to 70%, and has
been unchanged over the last several decades, despite ad-
vances in synthetic materials and extracorporeal circuits
for hemodialysis and hemofiltration [10]. This continu-
ing poor outcome in ICU patients with ATN may be due
to the fact that current hemodialysis and hemofiltration
therapies replace only the small solute clearance function
of the kidney but do not replace the kidney’s reclamation,
metabolic, and endocrine functions [7]. Since ATN devel-
ops predominantly due to the injury and necrosis of renal
proximal tubule cells, addition of these cellular functions
during hemofiltration should provide more complete re-
nal replacement therapy during the episode of ARF and
may alter the current natural history of this disorder.
Because of hemodialysis or hemofiltration interven-
tions, the cause of death in these ICU patients is no longer
due to hyperkalemia, acidemia, volume overload, or ure-
mia, but is most frequently due to a spiraling sequence
of events, initiated with the development of the SIRS,
often secondary to bacterial infection or sepsis, with re-
sulting cardiovascular collapse, ischemic damage to vital
organs, and MOF [11]. The addition of renal tubular cel-
lular metabolic activities to the current CRRT techniques
may provide added value to the therapeutic approach to
this disease state.
In this regard, an extracorporeal device utilizing a
standard hemofiltration cartridge containing approxi-
mately 109 renal proximal tubule cells grown from adult
stem/progenitor cells as confluent monolayers along the
inner surface of the fibers has been successfully fabri-
cated with human cells [25]. In vitro experiments utilizing
porcine or human proximal tubule progenitor cells have
shown differentiated transport and metabolic functions
of the RAD [4, 22, 25]. The bioartificial kidney set-up con-
sists of a filtration unit (a conventional synthetic hemofil-
tration cartridge) followed in series by the tubule (RAD)
unit. The tubule unit is able to maintain viability be-
cause oxygen along with metabolic substrates and growth
substances are delivered to the tubule cells from both
intraluminal ultrafiltrate and blood in the ECS. Immuno-
protection of the cells is achieved due to the impenetra-
bility of immunoglobulins and immunocompetent cells
across the hollow fibers. Rejection of nonautologous cells
does not occur.
Preclinical studies in large animals have demonstrated
that the bioartificial kidney (BAK) and RAD successfully
replaced filtration, transport, metabolic, and endocrino-
logic functions of the kidney in acutely uremic dogs [4].
Further preclinical experiments in acutely uremic dogs
have also evaluated the influence of the RAD under stress
states. Acutely nephrectomized animals were challenged
with infusions of endotoxin (lipopolysaccharide) intra-
venously or with intraperitoneal administration of doses
of viable Escherichia coli before treatment with either cell
or sham control RADs in a BAK [23, 24]. In these experi-
ments, cell RADs provided metabolic renal replacement
and resulted in higher IL-10 anti-inflammatory plasma
levels, better hemodynamic stability, and, in the E. coli
sepsis model, longer survival times compared to sham
controls. To further evaluate the role of the BAK in
septic shock, a swine model with normal kidney func-
tion was given large doses of E. coli intraperitoneally
[36]. All animals developed ATN with oligo/anuria within
two to four hours following administration, and RAD
treatment resulted in better cardiovascular performance,
lower plasma levels of the proinflammatory cytokines, IL-
6, and interferon (INF)-c, and longer survival times com-
pared to sham controls. These extensive preclinical data
provided support for the safety, functional performance,
and efficacy of the RAD in ARF and septic shock, allow-
ing a degree of confidence to pursue an evaluation of the
BAK in severely ill patients suffering from ATN.
This report details the initial clinical experience of the
BAK and RAD in 10 patients in the ICU setting with
ATN requiring CRRT. This experience has demonstrated
the safety, durability, viability, and functionality of this bi-
ologic therapy for up to 24 hours in this clinical setting.
Hypoglycemia, likely related to the release of nonspe-
cific bound insulin from the RAD during treatment, was
observed in one patient. Moderate to severe hypoten-
sion or hypovolemia was seen in a majority of patients.
The relationship of hypotension to RAD therapy, volume
shifts, or underlying disease processes could not be deter-
mined. A decline in platelet count or worsening of pre-
RAD thrombocytopenia was seen in some patients, but
no bleeding episodes were observed during treatment.
The RAD demonstrated device integrity, cell viability,
and metabolic functionality in these critically ill patients
for up to 24 hours. There was no evidence of membrane
breakage in the RAD cartridge. Cell loss during ther-
apy was less than 0.01% of the approximate initial num-
ber of cells within the RAD. Metabolic function of the
tubule cells was demonstrated throughout the treatment
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period as reflected by glutathione metabolism, and 1,25-
(OH)2-Vit D3 activation. The influence of RAD treat-
ment on systemic circulating cytokine levels was also
observed. The patients treated in this study had a wide
spectrum of plasma cytokine levels. The subset of patients
who presented with very high plasma cytokine levels and
who were treated for an adequate period showed that
RAD treatment resulted in significant reductions in G-
CSF, IL-6, and IL-10 levels. The reductions in IL-6 lev-
els are especially noteworthy, since IL-6 plasma levels
have been directly correlated to mortality rates in pa-
tients with SIRS [37]. Also, the greater relative reduc-
tion in IL-6 levels compared to IL-10 values suggests an
effect of renal tubule cell therapy to rebalance the ex-
cessive proinflammatory response with the concurrent
anti-inflammatory response. These results are consistent
with an immunomodulatory role of renal tubule cells in
patients with ATN and multiorgan failure.
Although primarily a safety study, the initial outcome
results in this small, uncontrolled trial were compelling
and relatively unexpected. The improvement in BUN and
serum creatinine prior to and after RAD therapy was
significant. But without a control, nontreated group, no
firm conclusions can be made. Several patients had re-
markable increases in urine output from their native kid-
neys that were temporally related to cell therapy [38].
This change may relate to improved renal blood flow,
which has been observed in preclinical septic animal mod-
els during RAD therapy [36]. The majority of patients
demonstrated improved APS scores within 1 to 7 days
of therapy, suggesting that RAD treatment was associ-
ated with improvement of multiple physiologic parame-
ters. Despite these initial improvements, four of the 10
patients died within 30 days and a fifth patient died on
day 60. One patient, at the family’s request, was removed
from life support within 12 hours following RAD treat-
ment, so that adequate assessment of RAD effect was
limited. The three other patients who subsequently died
all succumbed to existing comorbidities (SLE, diffuse
atherosclerosis, and toxic megacolon) unrelated to ATN
and RAD therapy.
An interesting observation from this study was that
renal cell therapy for 24 hours or less appears to have a
sustained effect on a patient’s clinical course over the sub-
sequent 3 to 7 days following therapy. The mechanism of
this observation is unclear, but future studies will follow
the time course of plasma cytokines to evaluate whether
short-term treatment with the RAD translates into long-
lasting effects to the inflammatory state of a critically ill
patient with ARF and MOF.
CONCLUSION
Despite the serious nature and multiple life-
threatening diagnoses of the 10 patients participating in
this initial evaluation of renal tubule cell therapy, the re-
view of the clinical, laboratory, and physiologic measure-
ments suggests that, with the exception of one report of
hypoglycemia, adverse events were limited to exacerba-
tion of thrombocytopenia and hypotension, of which the
latter usually occurred within the first 15 minutes of ther-
apy and responded to standard therapy. The RAD also
demonstrated functional and metabolic performance for
up to 24 hours of use in these patients. The influence of
treatment on native renal function, measurable effects
on circulating mediators of inflammation, and improved
mortality rates compared to those predicted by estab-
lished prognostic scoring systems require further evalua-
tion. In this regard, a Phase II multicenter, randomized,
controlled trial is underway to further assess the safety
and efficacy of renal tubule cell therapy in approximately
100 patients for up to 72 hours of continuous treatment.
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